铁蛋白、线粒体铁蛋白与神经变性疾病的关系
摘要
<正>铁蛋白(Ft)是调控铁代谢的关键蛋白,是反映铁储量的临床标志,由重链(FTH)和轻链(FTL)组成,FTH含有亚铁氧化酶活性,FTL亚基主要携带铁离子~[1]。线粒体铁蛋白(FtMt)是与FTH高度同源的位于线粒体内的铁蛋白。近年来研究~[2]发现Ft和/或FtMt在神经变性疾病的病理机制中发挥着重要作用,为明确神经变性疾病与Ft和/或FtMt的关系,我
引文
[1]Muhoberac BB,Vidal R.Front Aging Neurosci,2013,5:32.
[2]Gao G,Chang YZ.Front Pharmacol,2014,5:19.
[3]黄蕾,付蓉,邵宗鸿.中华血液学杂志,2012,33:884.
[4]中华医学会神经病学分会帕金森病及运动障碍学组.中华神经科杂志,2009,42:709.
[5]Snyder AM,Wang X,Patton SM,et al.J Neuropathol Exp Neurol,2009,68:1193.
[6]谭利娜,卫海燕,张耀东,等.中国当代儿科杂志,2011,13:722.
[7]Wang L,Yang H,Zhao S,et al.PLo S One,2011,6:e22325.
[8]Quintana C,Bellefqih S,Laval JY,et al.J Struct Biol,2006,153:42.
[9]Liu B,Moloney A,Meehan S,et al.J Biol Chem,2011,286:4248.
[10]Wu WS,Zhao YS,Shi ZH,et al.Antioxid Redox Signal,2013,18:158.
[11]Madenci G,Bilen S,Arli B,et al.Neurochem Res,2012,37:1436.
[12]詹晓燕,林玉蓓,刘卫国,等.国际检验医学杂志,2011,32:2069.
[13]Visanji NP,Collingwood JF,Finnegan ME,et al.J Parkinsons Dis,2013,3:523.
[14]郭小明,陈静,孙相如.中国综合临床,2010,26:271.
[15]Levi S,Finazzi D.Front.Pharmacol,2014,5:99.
[16]Miyajima H.Neuropathology,2015,35:83.
[17]Ohta E.Rinsho Shinkeigaku,2012,52:951.
[18]Nishida K,Garringer HJ,Futamura N,et al.J Neurol Sci,2014,342:173.
[19]Ohta E,Takiyama Y.Neurol Res Int,2012,2012:197438.
[20]Singh P,Saggar K,Kaur M,et al.J Pediatr Neurosci,2012,7:27.
[21]Mahmoud MM,El-Mazary AA,Maher RM,et al.Ital J Pediatr,2011,37:60.
[22]Oner P,Oner O,Azik FM,et al.Pediatr Int,2012,54:688.
[23]Romanos M,Tiesler CM,Koletzko S,et al.Atten Defic Hyperact Disord,2013,5:313.
[24]Campanella A,Rovelli E,Santambrogio P,et al.Hum Mol Genet,2009,18:1.
[25]Koeppen AH,Michael SC,Knutson MD,et al.Acta Neuropathol,2007,114:163.
[2]Gao G,Chang YZ.Front Pharmacol,2014,5:19.
[3]黄蕾,付蓉,邵宗鸿.中华血液学杂志,2012,33:884.
[4]中华医学会神经病学分会帕金森病及运动障碍学组.中华神经科杂志,2009,42:709.
[5]Snyder AM,Wang X,Patton SM,et al.J Neuropathol Exp Neurol,2009,68:1193.
[6]谭利娜,卫海燕,张耀东,等.中国当代儿科杂志,2011,13:722.
[7]Wang L,Yang H,Zhao S,et al.PLo S One,2011,6:e22325.
[8]Quintana C,Bellefqih S,Laval JY,et al.J Struct Biol,2006,153:42.
[9]Liu B,Moloney A,Meehan S,et al.J Biol Chem,2011,286:4248.
[10]Wu WS,Zhao YS,Shi ZH,et al.Antioxid Redox Signal,2013,18:158.
[11]Madenci G,Bilen S,Arli B,et al.Neurochem Res,2012,37:1436.
[12]詹晓燕,林玉蓓,刘卫国,等.国际检验医学杂志,2011,32:2069.
[13]Visanji NP,Collingwood JF,Finnegan ME,et al.J Parkinsons Dis,2013,3:523.
[14]郭小明,陈静,孙相如.中国综合临床,2010,26:271.
[15]Levi S,Finazzi D.Front.Pharmacol,2014,5:99.
[16]Miyajima H.Neuropathology,2015,35:83.
[17]Ohta E.Rinsho Shinkeigaku,2012,52:951.
[18]Nishida K,Garringer HJ,Futamura N,et al.J Neurol Sci,2014,342:173.
[19]Ohta E,Takiyama Y.Neurol Res Int,2012,2012:197438.
[20]Singh P,Saggar K,Kaur M,et al.J Pediatr Neurosci,2012,7:27.
[21]Mahmoud MM,El-Mazary AA,Maher RM,et al.Ital J Pediatr,2011,37:60.
[22]Oner P,Oner O,Azik FM,et al.Pediatr Int,2012,54:688.
[23]Romanos M,Tiesler CM,Koletzko S,et al.Atten Defic Hyperact Disord,2013,5:313.
[24]Campanella A,Rovelli E,Santambrogio P,et al.Hum Mol Genet,2009,18:1.
[25]Koeppen AH,Michael SC,Knutson MD,et al.Acta Neuropathol,2007,114:163.